Expression patterns of CD33 and CD15 predict outcome in patients with acute myeloid leukemia

References

• Lowenberg B, Griffin J D, Tallman M S. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Prog 2003; 1: 82–101
   Google Scholar
• Haferlach T, Kern W, Schnittger S, Schoch C. Modern diagnostics in acute leukemias. Crit Rev Oncol Hematol 2005; 56: 223–234
   PubMed Web of Science ®Google Scholar
• Haferlach T, Kohlmann A, Schnittger S, Dugas M, Hiddemann W, Kern W, et al. Global approach to the diagnosis of leukemia using gene expression profiling. Blood 2005; 106: 1189–1198
   PubMed Web of Science ®Google Scholar
• Mrozek K, Marcucci G, Paschka P, Whitman S P, Bloomfield C D. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?. Blood 2007; 109: 431–448
   PubMed Web of Science ®Google Scholar
• Buechner T, Berdel W E, Schoch C, Haferlach T, Serve H L, Schnittger S, et al. Treatment of AML in biological subgroups. Hematology 2005; 10(Suppl. 1)281–285
   PubMed Web of Science ®Google Scholar
• Mrozek K, Heerema N A, Bloomfield C D. Cytogenetics in acute leukemia. Blood Rev 2004; 18: 115–136
   PubMed Web of Science ®Google Scholar
• Rund D, Krichevsky S, Bar-Cohen S, Goldschmidt N, Kedmi M, Malik E, et al. Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients. Leukemia 2005; 19: 1919–1928
   PubMed Web of Science ®Google Scholar
• San Miguel J F, Hernandez J M, Gonzalez-Sarmiento R, Gonzalez M, Sanchez I, Orfao A, et al. Acute leukemia after a primary myelodysplastic syndrome: immunophenotypic, genotypic, and clinical characteristics. Blood 1991; 78: 768–774
   PubMed Web of Science ®Google Scholar
• Buchner T, Berdel W E, Schoch C, Haferlach T, Serve H L, Kienast J, et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006; 24: 2480–2489
   PubMed Web of Science ®Google Scholar
• Boissel N, Cayuela J M, Preudhomme C, Thomas X, Grardel N, Fund X, et al. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia 2002; 16: 1699–1704
   PubMed Web of Science ®Google Scholar
• Palmieri S, Ferrara F, Leoni F, Ciolli S, Pollio F, D'Amico M R, et al. Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype. Hematol Oncol 2007; 25: 1–5
   PubMed Web of Science ®Google Scholar
• Frohling S, Schlenk R F, Breitruck J, Benner A, Kreitmeier S, Tobis K, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002; 100: 4372–4380
   PubMed Web of Science ®Google Scholar
• Falini B, Nicoletti I, Martelli M F, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc + AML): biological and clinical features. Blood 2007; 109: 874–885
   PubMed Web of Science ®Google Scholar
• Basso G, Buldini B, De Z L, Orfao A. New methodologic approaches for immunophenotyping acute leukemias. Haematologica 2001; 86: 675–692
   PubMed Web of Science ®Google Scholar
• Macedo A, Orfao A, Vidriales M B, Lopez-Berges M C, Valverde B, Gonzalez M, et al. Characterization of aberrant phenotypes in acute myeloblastic leukemia. Ann Hematol 1995; 70: 189–194
   PubMed Web of Science ®Google Scholar
• Hrusak O, Porwit-MacDonald A. Antigen expression patterns reflecting genotype of acute leukemias. Leukemia 2002; 16: 1233–1258
   PubMed Web of Science ®Google Scholar
• Mason K D, Juneja S K, Szer J. The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis?. Blood Rev 2006; 20: 71–82
   PubMed Web of Science ®Google Scholar
• Edvardsson L, Dykes J, Olsson M L, Olofsson T. Clonogenicity, gene expression and phenotype during neutrophil versus erythroid differentiation of cytokine-stimulated CD34+human marrow cells in vitro. Br J Haematol 2004; 127: 451–463
   PubMed Web of Science ®Google Scholar
• Grimwade D. The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001; 14: 497–529
   PubMed Web of Science ®Google Scholar
• Bene M C, Castoldi G, Derolf A, Garand R, Haas T, Haferlach T, et al. Near-tetraploid acute myeloid leukemias: an EGIL retrospective study of 25 cases. Leukemia 2006; 20: 725–728
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, et al. Proposals for the classification of the acute leukaemias. French–American–British (FAB) co-operative group. Br J Haematol 1976; 33: 451–458
   PubMed Web of Science ®Google Scholar
• Vardiman J W, Harris N L, Brunning R D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292–2302
   PubMed Web of Science ®Google Scholar
• Rohatiner A ZS, Bassan R, Bjorkholm M, Rule S, Newland A C, Raimondi R. High-dose treatment (HDT) with peripheral blood progenitor cell (PBPC) support as consolidation of first remission in younger patients (PTS) with acute myelogenous leukemia (AML). Proc Am Soc Hematol 1998; 92: 293a, Abstract
   Google Scholar
• Lofgren C, Paul C, Astrom M, Hast R, Hedenius M, Lerner R, et al. Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial. Br J Haematol 2004; 124: 474–480
   PubMed Web of Science ®Google Scholar
• Hast R, Hellstrom-Lindberg E, Ohm L, Bjorkholm M, Celsing F, Dahl I M, et al. No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. Leukemia 2003; 17: 1827–1833
   PubMed Web of Science ®Google Scholar
• Juliusson G, Hoglund M, Karlsson K, Lofgren C, Mollgard L, Paul C, et al. Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. Br J Haematol 2003; 123: 810–818
   PubMed Web of Science ®Google Scholar
• Ringden O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelov L, et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723–2730
   PubMed Web of Science ®Google Scholar
• Solary E, Casasnovas R O, Campos L, Bene M C, Faure G, Maingon P, et al. Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR–-phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucemies (GEIL). Leukemia 1992; 6: 393–399
   PubMed Web of Science ®Google Scholar
• Ciolli S, Leoni F, Caporale R, Pascarella A, Salti F, Rossi-Ferrini P. CD34 expression fails to predict the outcome in adult acute myeloid leukemia. Haematologica 1993; 78: 151–155
   PubMed Web of Science ®Google Scholar
• Bradstock K, Matthews J, Benson E, Page F, Bishop J. Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Blood 1994; 84: 1220–1225
   PubMed Web of Science ®Google Scholar
• Basso G, Lanza F, Orfao A, Moretti S, Castoldi G. Clinical and biological significance of CD34 expression in acute leukemia. J Biol Regul Homeost Agents 2001; 15: 68–78
   PubMed Web of Science ®Google Scholar
• Schwartz S, Heinecke A, Zimmermann M, Creutzig U, Schoch C, Harbott J, et al. Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance. Leuk Lymphoma 1999; 34: 85–94
   PubMed Web of Science ®Google Scholar
• Baer M R, Stewart C C, Lawrence D, Arthur D C, Byrd J C, Davey F R, et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 1997; 90: 1643–1648
   PubMed Web of Science ®Google Scholar
• Raspadori D, Damiani D, Lenoci M, Rondelli D, Testoni N, Nardi G, et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia 2001; 15: 1161–1164
   PubMed Web of Science ®Google Scholar
• Chang H, Salma F, Yi Q L, Patterson B, Brien B, Minden M D. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res 2004; 28: 43–48
   PubMed Web of Science ®Google Scholar
• Di B E, Sartori R, Zambello R, Guercini N, Madeo D, Rodeghiero F. Prognostic significance of CD56 antigen expression in acute myeloid leukemia. Haematologica 2002; 87: 250–256
   PubMed Web of Science ®Google Scholar
• Tien H F, Wang C H, Lin M T, Lee F Y, Liu M C, Chuang S M, et al. Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan. Cancer Genet Cytogenet 1995; 84: 60–68
   PubMed Web of Science ®Google Scholar
• Schwarzinger I, Valent P, Köller U, Marosi C, Schneider B, Haas O, et al. Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. J Clin Oncol 1990; 8: 423–430
   PubMed Web of Science ®Google Scholar
• Griffin J D, Davis R, Nelson D A, Davey F R, Mayer R J, Schiffer C, et al. Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. Blood 1986; 68: 1232–1241
   PubMed Web of Science ®Google Scholar
• Campos L, Guyotat D, Archimbaud E, Devaux Y, Treille D, Larese A, et al. Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy. Br J Haematol 1989; 72: 161–166
   PubMed Web of Science ®Google Scholar
• Casasnovas R O, Campos L, Mugneret F, Charrin C, Bene M C, Garand R, et al. Immunophenotypic patterns and cytogenetic anomalies in acute non-lymphoblastic leukemia subtypes: a prospective study of 432 patients. Leukemia 1998; 12: 34–43
   PubMed Web of Science ®Google Scholar
• Legrand O, Perrot J Y, Baudard M, Cordier A, Lautier R, Simonin G, et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood 2000; 96: 870–877
   PubMed Web of Science ®Google Scholar
• Repp R, Schaekel U, Helm G, Thiede C, Soucek S, Pascheberg U, et al. Immunophenotyping is an independent factor for risk stratification in AML. Cytometry B Clin Cytom 2003; 53: 11–19
   PubMed Web of Science ®Google Scholar
• Munoz L, Aventin A, Villamor N, Junca J, Acebedo G, Domingo A, et al. Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication. Haematologica 2003; 88: 637–645
   PubMed Web of Science ®Google Scholar
• Lin L I, Chen C Y, Lin D T, Tsay W, Tang J L, Yeh Y C, et al. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 2005; 11: 1372–1379
   PubMed Web of Science ®Google Scholar
• Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli M F, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005; 106: 3733–3739
   PubMed Web of Science ®Google Scholar
• Bienz M, Ludwig M, Leibundgut E O, Mueller B U, Ratschiller D, Solenthaler M, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 2005; 11: 1416–1424
   PubMed Web of Science ®Google Scholar